Supplementary material 4. Subgroup analysis results of peripheral blood lymphocytes levels (Figures S1-24)




Figure S1 Subgroups analysis of CD3+T cells by KPS score




Figure S2 Subgroups analysis of CD3+CD4+T cells by KPS score




Figure S3 Subgroups analysis of CD4+/CD8+T cells by KPS score




Figure S4 Subgroups analysis of CD3+T cells by anticipated survival time




Figure S5 Subgroups analysis of CD3+CD4+T cells by anticipated survival time




Figure S6 Subgroups analysis of CD4+/CD8+T cells by anticipated survival time




Figure S7 Subgroups analysis of CD3⁺T cells by treatment process




Figure S8 Subgroups analysis of CD3+CD4+T cells by treatment process




Figure S9 Subgroups analysis of CD4+/CD8+T cells by treatment process




Figure S10 Subgroups analysis of CD3⁺T cells by age




Figure S11 Subgroups analysis of CD3+CD4+T cells by age




Figure S12 Subgroups analysis of CD4+/CD8+T cells by age




Figure S13 Subgroups analysis of CD3⁺T cells by dosage of Aidi injection

	Aidi injection		Gemcitabine and cisplatin			Std. Mean Difference			Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
50-60ml										
Zhang, H.2014	38.11	3.15	64	34.23	3.43	64	6.6%	1.17 [0.80, 1.55]	2014	-
Li, X.2015	38.11	5.31	20	36.76	4.69	20	5.8%	0.26 [-0.36, 0.89]	2015	
Han, R.2015	34.16	5.25	36	23.28	5.36	36	6.0%	2.03 [1.45, 2.60]	2015	-
Ma, M.2017	22.36	5.04	42	16.45	2.58	42	6.3%	1.46 [0.98, 1.95]	2017	_
Huang, W.2017	33.34	5.18	39	28.92	3.93	40	6.3%	0.95 [0.49, 1.42]	2017	-
Su, S.2017	42.9	4.89	40	33.32	5.16	39	6.1%	1.89 [1.35, 2.42]	2017	-
Wu, Y.2017	38.11	5.31	109	36.76	4.69	109	6.9%	0.27 [0.00, 0.54]	2017	~
Lv, W.2018	36	3	30	30	2	30	5.7%	2.32 [1.66, 2.99]	2018	
Liu, H.2019	36.01	4.13	44	33.38	2.55	44	6.5%	0.76 [0.33, 1.19]	2019	-
Zhao,J.2019	39.91	5.08	43	34.82	5.47	43	6.4%	0.96 [0.51, 1.40]	2019	-
Tan, H.2020	36.26	5.48	60	30.48	4.17	60	6.6%	1.18 [0.79, 1.57]	2020	_
Guo, X.2020	47.26	4.28	51	40.17	2.35	51	6.3%	2.04 [1.56, 2.52]	2020	_ _
Subtotal (95% CI)			578			578	75.5%	1.26 [0.87, 1.64]		•
Heterogeneity: Tau ² = 0.40; Chi ² = 95.59, df = 11 (P < 0.00001); I ² = 88%										
Test for overall effect:	Z = 6.44	(P < 0	.00001))						
90-100ml										
Jiang,S.2011	37.6	5.4	32	26.3	6.5	30	5.9%	1.87 [1.27, 2.48]	2011	
Zhao, S.2015	35.11	1.53	43	30.25	2.66	43	6.1%	2.22 [1.68, 2.76]	2015	
Subtotal (95% CI)			75			73	12.0%	2.06 [1.66, 2.47]		•
Heterogeneity: Tau ² = 0.00; Chi ² = 0.70, df = 1 (P = 0.40); i ² = 0%										
Test for overall effect: Z = 10.03 (P < 0.00001)										
Others										
Li, J.2016	35.2	3.1	47	29.3	2.7	47	6.2%	2.01 [1.51, 2.51]	2016	-
Xu,Z.2020	36.36	4.25	40	32.96	2.05	40	6.3%	1.01 [0.54, 1.48]	2020	
Subtotal (95% CI)			87			87	12.6%	1.51 [0.52, 2.49]		•
Heterogeneity: Tau² = 0.44; Chi² = 8.28, df = 1 (P = 0.004); i² = 88%										
Test for overall effect:	Z = 3.00	(P = 0	.003)							
Total (95% CI)			740			738	100.0%	1.38 [1.04, 1.72]		•
Heterogeneity: Tau ² = 0.42; Chi ² = 129.01, df = 15 (P < 0.00001); i ² = 88%										
Test for everall effect: 7 - 7.97 (P < 0.00001)										
Favours [Gemcitabine and cisplatin] Favours [Aidi injection]										

Figure S14 Subgroups analysis of CD3+CD4+T cells by dosage of Aidi injection




Figure S15 Subgroups analysis of CD4+/CD8+T cells by dosage of Aidi injection




Figure S16 Subgroups analysis of CD3+T cells by treatment time




Figure S17 Subgroups analysis of CD3+CD4+T cells by treatment time




Figure S18 Subgroups analysis of CD4⁺/CD8⁺ T cells by treatment time




Figure S19 Subgroups analysis of CD3⁺T cells by treatment cycle




Figure S20 Subgroups analysis of CD3+CD4+T cells by treatment cycle




Figure S21 Subgroups analysis of CD4⁺/CD8⁺ T cells by treatment cycle




Figure S22 Subgroups analysis of CD3+T cells by cisplatin dosage




Figure S23 Subgroups analysis of CD3⁺ CD4⁺ T cells by cisplatin dosage




Figure S24 Subgroups analysis of CD4+/CD8+T cells by cisplatin dosage